Enterprise Value to EBITDA Ratio: BeiGene, Ltd. (BGNE)
BeiGene, Ltd. (BGNE) is advancing biopharmaceuticals by combining internal resources with the engagement of third-party CDMOs and CROs, which creates a dependency on external quality. This chart confirms a market EV/EBITDA valuation of 29.61. The success of expansion across the US, China, and Europe relies on government pricing policies and regulators. The company is currently expanding distribution in Asia, increasing its patient base through new approvals for the treatment of hematologic malignancies.
beigene.com (BGNE) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
BGNE - Company Net Income|Expected Profit BeiGene, Ltd.|BGNE - Price to Earnings Multiple|Forward P/E Multiple BeiGene, Ltd.|BGNE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio BeiGene Ltd|BGNE - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months BeiGene|BGNE - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months beigene.com|BGNE - Net earnings per one share growth for the current year|Earnings growth forecast for next year BeiGene, Ltd.
- company sales and revenue statistics:
Initial company analysis:BeOne Medicines BGNE
BeiGene, Ltd. (BGNE) is scaling its global oncology presence, requiring significant capital expenditures for the development of innovative drugs. This EV/EBITDA chart allows for an assessment of the total business value relative to its operating profit before depreciation and interest. A decline in this multiple may signal that the asset is undervalued; however, it is critical for investors to distinguish between searching for a local bottom and a fundamental devaluation of the business.
Analysis of competing companies
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DCTH (delcath.com)|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc (AURA) - Company Value to EBITDA|Candel - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Accuray, Inc. ARAY|SLS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple actuatetherapeutics.com ACTU|CTOR (Citius Oncology) - EV/EBITDA Multiple|Company Value to EBITDA TuHURA HURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|Fate Pharma - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Company Value to EBITDA|CSBR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc.)|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OSTX (OS Therapies, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio RADX|ARTV (Artiva) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ANL|Veru Inc - Enterprise Value to Operating Income Before Depreciation|Tempest Tx - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Xilio Therapeutics Inc (XLO)|Enochian BioSciences - EV/EBITDA Multiple|MURA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KAPA: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple OnKure Therapeutics OKUR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytoMed Therapeutics Ltd|Enterprise Value to Operating Income Before Depreciation CRIS (Curis Corp)|EV/EBITDA Multiple APLM|THAR - Company Value to EBITDA|EV/EBITDA Multiple ADVB (Advanced Biomed)|GNPX - Enterprise Value to EBITDA Ratio|Calidi Bio - EV/EBITDA Multiple|SBFM - EV/EBITDA Multiple|xeneticbio.com (XBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SLRX|PPBT (Purple Biotech Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio AON (AONC)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|Business Value to Operating Income Before Depreciation IKNA|NTBL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics)|MOR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NAYA Biosciences Corp|Enterprise Value to EBITDA Ratio AAPGV
